skip to main content
Idioma:

High-Flow Nasal Cannula Therapy in Children With Acute Respiratory Distress With Hypoxia in A Pediatric Intensive Care UnitA Single Center Experience

Chang, Chih-Ching ; Lin, Yi-Chen ; Chen, Tzu-Chun ; Lin, Jainn-Jim ; Hsia, Shao-Hsuan ; Chan, Oi-Wa ; Lee, En-Pei

Frontiers in pediatrics, 2021-05, Vol.9, p.664180-664180 [Periódico revisado por pares]

Frontiers Media S.A

Texto completo disponível

Citações Citado por
  • Título:
    High-Flow Nasal Cannula Therapy in Children With Acute Respiratory Distress With Hypoxia in A Pediatric Intensive Care UnitA Single Center Experience
  • Autor: Chang, Chih-Ching ; Lin, Yi-Chen ; Chen, Tzu-Chun ; Lin, Jainn-Jim ; Hsia, Shao-Hsuan ; Chan, Oi-Wa ; Lee, En-Pei
  • Assuntos: Pediatrics
  • É parte de: Frontiers in pediatrics, 2021-05, Vol.9, p.664180-664180
  • Notas: ObjectType-Article-1
    SourceType-Scholarly Journals-1
    ObjectType-Feature-2
    content type line 23
    Edited by: Phuc Huu Phan, Vietnam National Hospital of Pediatrics, Vietnam
    These authors have contributed equally to this work
    Reviewed by: Dincer Riza Yildizdas, ukurova University, Turkey; Jhuma Sankar, All India Institute of Medical Sciences, India
    This article was submitted to Pediatric Critical Care, a section of the journal Frontiers in Pediatrics
  • Descrição: Aim: High-flow nasal cannulas (HFNCs) show potential in the application of positive pressure, improving gas exchange, and decreasing work of breathing in patients with acute respiratory distress. The aims of this study were to elucidate the indications for HFNC therapy in children of all ages and diagnoses, and to evaluate the efficacy and risk factors for failure of HFNC therapy in children with acute respiratory distress with hypoxia in a pediatric intensive care unit. Methods: We conducted this retrospective cohort study at a tertiary pediatric intensive care unit between January 1, 2018 and December 31, 2020. All children, from 1 month to 18 years of age, with acute respiratory distress with hypoxia and HFNC therapy were eligible. The clinical data were reviewed. Results: One hundred and two children met the eligibility criteria for the study, of whom 57 (55.9%) were male, and the mean age was 7.00 6.79 years. Seventy-eight (76.5%) of the children had underlying disorders. The most common indications for the use of HFNC therapy were pneumonia (40, 39.2%), sepsis-related respiratory distress (17, 16.7%), and bronchiolitis (16, 15.7%). The failure rate was 15.7% (16 of 102 children). Higher initial and maximum fraction of inspiration O2 levels and lower initial and lowest SpO2/FiO2 (S/F) ratio were early and possible signs of failure requiring escalation of respiratory support. Conclusion: In our population, we found that HFNC therapy could be initiated as the first-line therapy for various etiologies of acute respiratory distress with hypoxia in a pediatric intensive care unit and for all age groups.
  • Editor: Frontiers Media S.A
  • Idioma: Inglês
Voltar para lista de resultados

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.